Pharmacogenetic‐guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC‐PGx): A multicenter clinical trial

Pharmacogenetic‐guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC‐PGx): A multicenter clinical trial

Abstract PACIFIC‐PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of DPYD/UGT1A1 genotype‐guided dosing on severe fluoropyrimidine (FP) and irinotecan‐related toxicities and hospitalizations, compared to historical controls. This prospective...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah Glewis, Senthil Lingaratnam, Benjamin Lee, Ian Campbell, Maarten IJzerman, Mussab Fagery, Sam Harris, Chloe Georgiou, Craig Underhill, Mark Warren, Robert Campbell, Madawa Jayawardana, S. Sandun M. Silva, Jennifer H. Martin, Jeanne Tie, Marliese Alexander, Michael Michael
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70083
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70083

Similar Items